Compounds and methods for treatment of stroke

Abstract

The present invention relates to methods and agents useful for the treatment of stroke, including ischemic stroke and hemorrhagic stroke. In particular, methods and agents for treating stroke in a subject are provided, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a hemorrhagic stroke.

1 . A method for treating stroke in a subject, the method comprising administering to the subject an effective amount of an agent that inhibits hypoxia inducible factor (HIF) hydroxylase activity, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a hemorrhagic stroke.  
   
   
       2 . The method of  claim 1 , wherein the subject has diabetes.  
   
   
       3 . The method of  claim 1 , wherein the agent is a 2-oxoglutarate mimetic.  
   
   
       4 . A method for treating or ameliorating brain tissue damage associated with stroke in a subject, the method comprising administering to the subject an effective amount of an agent that inhibits hypoxia inducible factor (HIF) hydroxylase activity.  
   
   
       5 . The method of  claim 4 , wherein the brain tissue damage is infarct volume.  
   
   
       6 . The method of  claim 4 , wherein the brain tissue damage is edema.  
   
   
       7 . The method of  claim 4 , wherein the brain tissue damage is a lesion.  
   
   
       8 . The method of  claim 4 , wherein the brain tissue damage is neuronal degeneration.  
   
   
       9 . The method of  claim 4 , wherein the brain tissue damage is brain tissue loss.  
   
   
       10 . The method of  claim 4 , wherein the subject has diabetes.  
   
   
       11 . The method of  claim 4 , wherein the agent is a 2-oxoglutarate mimetic.  
   
   
       12 . A method for treating or ameliorating brain tissue damage associated with stroke in a subject, the method comprising administering to the subject an effective amount of an agent that inhibits hypoxia inducible factor (HIF) hydroxylase activity, wherein the agent is administered more than 3 hours after the time of stroke onset.  
   
   
       13 . A method for improving or restoring sensorimotor function in a subject having had a stroke, the method comprising administering to the subject an effective amount of an agent that inhibits hypoxia inducible factor (HIF) hydroxylase activity.  
   
   
       14 . A method for improving or restoring neuromuscular function in a subject having had a stroke, the method comprising administering to the subject an effective amount of an agent that inhibits hypoxia inducible factor (HIF) hydroxylase activity.